YHLO and South Korea's SDB carry out strategic cooperation talks to expand global market layout
Recently, Mr. Hu Deming, the founder of YHLO, Mr. Hu Kunhui, the chairman of YHLO, and a high-level delegation visited the headquarter of SD Biosensor (stock code KRX: 137310) in South Korea, and had an in-depth communication and strategic cooperation negotiation with the senior management of SDB.
Meanwhile, during the trip to South Korea, YHLO senior management also met with the senior management of Sugentech, another local leading company in the field of medical diagnostics, which is dedicated to the research and development and production of products in the field of personal diagnostics. They had an in-depth communication and discussion on the cooperation of self-immunization and allergen testing.
Wondfo's revenue exceed RMB 2.7 billion by 2023
In 2023, the Company realized total revenue of RMB 2.765 billion and net profit attributable to shareholders of listed companies of RMB 488 million.In the first quarter of 2024, the Company realized total revenue of RMB 861 million, representing an increase of 3.54% over the same period of the previous year, and net profit attributable to shareholders of listed companies of RMB 218 million, representing an increase of 7.20% over the same period of the previous year.
In 2023, the four major regular businesses of Wondfo grew strongly, including the infectious disease business, which realized operating revenues of RMB 952 million; chronic disease management testing revenues of RMB 1,119 million, a year-on-year increase of 19.11%; drug (substance abuse) testing revenues of RMB 331 million, a year-on-year increase of 12.68%; and eugenics testing revenues of RMB 267 million, a year-on-year increase of 10.08%.
BioM¨¦rieux continues to ramp up! Hybiome inaugurated its new factory
On April 12, Alain M¨¦rieux, President of France M¨¦rieux Foundation, and his entourage visited Hybiome to witness the unveiling of the "Horse Statue" sculpture of M¨¦rieux (Suzhou) and the inauguration of the new plant of Hybiome.
The inauguration of the new plant is an important step to accelerate the expansion of Hybiome into the field of in vitro diagnostic frontier technology, and is also a vivid manifestation of bioM¨¦rieux's continuous investment in Suzhou Hi-Tech Zone, which will build the most competitive in vitro diagnostic leading enterprise in China. After the official commissioning and reaching the maximum design capacity in the future, it is expected that the annual production capacity of fully automated chemiluminescent immunoassay systems will be 1,000 sets, which will result in an annual output value of RMB 1 billion.
Siemens Healthcare partners with CHESS Liver Health Alliance
On April 15, Siemens Healthcare announced that the "Medical-Industrial Cross-Innovation Workstation" was recently inaugurated by the CHESS Liver Health Alliance and Siemens Healthcare, which is empowered by Southeast University's national medical research industry-education integration innovation platform. The "Medical-Industrial Cross-Innovation Workstation" will be located in Siemens Healthcare Shanghai Innovation Center. The two sides initially plan to explore the mechanism and system of medical-industrial cross-innovation around the construction of chronic liver disease, and promote the comprehensive promotion and clinical transformation of scientific and technological innovations.
